Sulofenur

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 205995

CAS#: 10311-27-8

Description: Sulofenur is a diarylsulfonylurea with potential antineoplastic activity. Sulofenur's antineoplastic mechanism of action is unknown.


Chemical Structure

img
Sulofenur
CAS# 10311-27-8

Theoretical Analysis

MedKoo Cat#: 205995
Name: Sulofenur
CAS#: 10311-27-8
Chemical Formula: C16H15ClN2O3S
Exact Mass: 350.04919
Molecular Weight: 350.82
Elemental Analysis: C, 54.78; H, 4.31; Cl, 10.11; N, 7.99; O, 13.68; S, 9.14s

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Sulofenur; LY186641; LY-186641; LY 186641.

IUPAC/Chemical Name: N-((4-chlorophenyl)carbamoyl)-2,3-dihydro-1H-indene-5-sulfonamide

InChi Key: JQJSFAJISYZPER-UHFFFAOYSA-N

InChi Code: InChI=1S/C16H15ClN2O3S/c17-13-5-7-14(8-6-13)18-16(20)19-23(21,22)15-9-4-11-2-1-3-12(11)10-15/h4-10H,1-3H2,(H2,18,19,20)

SMILES Code: O=S(C1=CC2=C(CCC2)C=C1)(NC(NC3=CC=C(Cl)C=C3)=O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >5 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 350.82 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Guan X, Hoffman BN, McFarland DC, Gilkerson KK, Dwivedi C, Erickson AK, Bebensee S, Pellegrini J. Glutathione and mercapturic acid conjugates of sulofenur and their activity against a human colon cancer cell line. Drug Metab Dispos. 2002 Mar;30(3):331-5. PubMed PMID: 11854154.

2: Jochheim CM, Davis MR, Baillie KM, Ehlhardt WJ, Baillie TA. Glutathione-dependent metabolism of the antitumor agent sulofenur. Evidence for the formation of p-chlorophenyl isocyanate as a reactive intermediate. Chem Res Toxicol. 2002 Feb;15(2):240-8. PubMed PMID: 11849051.

3: Krarup-Hansen A, Pedersen H, Andersen E, Andersen H, Hansen HH. Early clinical investigation of sulofenur with a daily schedule in advanced solid tumours. Invest New Drugs. 1997;15(2):147-51. PubMed PMID: 9220294.

4: Gu H, Smith MW, Phelps PC, Berezesky IK, Merriman RL, Boder GB, Trump BF. H-ras transfection of the rat kidney cell line NRK-52E results in increased induction of c-fos, c-jun and hsp70 following sulofenur treatment. Cancer Lett. 1996 Sep 10;106(2):199-205. PubMed PMID: 8844973.

5: Phelps PC, Best CJ, Berezesky IK, Merriman RL, Tanzer LR, Boder GB, Trump BF. Studies on the mechanism of sulofenur and LY295501 toxicity: effect on the regulation of cytosolic calcium in relation to cytotoxicity in normal and tumorigenic rat kidney cell lines. Cancer Lett. 1995 Oct 20;97(1):7-15. PubMed PMID: 7585481.

6: Houghton PJ, Cheshire PJ, Myers L, Lutz L, Toth J, Grindey GB, Houghton JA. Efficacy of sulofenur and a second generation diarylsulfonylurea, N-[5-(2,3-dihydrobenzofuryl)sulfonyl]-N'-(3,4-dichlorophenyl)urea (LY295501), against colon adenocarcinoma xenografts. Anticancer Drugs. 1995 Apr;6(2):317-23. PubMed PMID: 7795279.

7: Houghton PJ, Sosinski J, Thakar JH, Boder GB, Grindey GB. Characterization of the intracellular distribution and binding in human adenocarcinoma cells of N-(4-azidophenylsulfonyl)-N'-(4-chlorophenyl)urea (LY219703), a photoaffinity analogue of the antitumor diarylsulfonylurea sulofenur. Biochem Pharmacol. 1995 Mar 1;49(5):661-8. PubMed PMID: 7887981.

8: Phelps PC, Jain PT, Berezesky IK, Boder GB, Trump BF. Sulofenur cytotoxicity and changes in cytosolic calcium and mitochondrial membrane potential in human colon adenocarcinoma cell lines. Cancer Lett. 1995 Jan 6;88(1):27-35. PubMed PMID: 7850770.

9: Pratt CB, Bowman LC, Marina N, Pappo A, Avery L, Luo X, Meyer WH. A phase I study of sulofenur in refractory pediatric malignant solid tumors. Invest New Drugs. 1995;13(1):63-6. PubMed PMID: 7499110.

10: Brown TD, O'Rourke TJ, Kuhn JG, Craig JB, Havlin K, Burris HA 3rd, Cagnola J, Hamilton JM, Grindey GB, Satterlee WG, et al. Phase I trial of sulofenur (LY186641) given orally on a daily x 21 schedule. Anticancer Drugs. 1994 Apr;5(2):151-9. PubMed PMID: 8049498.



Additional Information